Sp398

DRUG SPECIFIC PREDICTION MODELS FOR POINT-OF-CARE IBD DECISION SUPPORT

Date
May 7, 2023
Explore related products in the following collection:

Society: AGA

Over the past decade, big data and artificial intelligence (AI) have become standard concepts in digestive disease research, both as individual tools and applied together. Artificial intelligence algorithms and large datasets are now applied to everything from unraveling the pathophysiology of disease mechanisms in model systems to precisely selecting the most appropriate treatment courses for patients. Speakers in this session will provide examples where big data and artificial intelligence have successfully advanced science and patient care, where these tools have failed to live up to expectations, and provide perspective on overcoming obstacles to further developing the tools. The session will focus on three thematic areas where AI and big data impact GI: clinical databases and natural language processing, biological datasets, and imaging.

Presenter

Speaker Image for Parambir Dulai
Northwestern University Feinberg School of Medicine

Tracks

Related Products

Thumbnail for PLACEHOLDER
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
Thumbnail for A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for PLACEHOLDER
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for INTRODUCTION
INTRODUCTION
SOCIETY: AGA